Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). METHODS: In this ongoing phase 3, multicenter, randomized, double-blind, placebo-controlled trial, we assigned 1197 patients with biopsy-defined MASH and fibrosis stage 2 or 3 in a 2:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo for 240 weeks. The results of a planned interim analysis conducted at week 72 involving the first 800 patients are reported here (part 1). The primary end points for part 1 were the resolution of steatohepatitis without worsening of liver fibrosis and reduction in liver fibrosis without worsening of steatohepatitis. RESULTS: Resolution of steatohepatitis without worsening of fibrosis occurred in 62.9% of the 534 patients in the semaglutide group and in 34.3% of the 266 patients in the placebo group (estimated difference, 28.7 percentage points; 95% confidence interval [CI], 21.1 to 36.2; P<0.001). A reduction in liver fibrosis without worsening of steatohepatitis was reported in 36.8% of the patients in the semaglutide group and in 22.4% of those in the placebo group (estimated difference, 14.4 percentage points; 95% CI, 7.5 to 21.3; P<0.001). Results for the three secondary outcomes that were included in the plan to adjust for multiple testing were as follows: combined resolution of steatohepatitis and reduction in liver fibrosis was reported in 32.7% of the patients in the semaglutide group and in 16.1% of those in the placebo group (estimated difference, 16.5 percentage points; 95% CI, 10.2 to 22.8; P<0.001). The mean change in body weight was -10.5% with semaglutide and -2.0% with placebo (estimated difference, -8.5 percentage points; 95% CI, -9.6 to -7.4; P<0.001). Mean changes in bodily pain scores did not differ significantly between the two groups. Gastrointestinal adverse events were more common in the semaglutide group. CONCLUSIONS: In patients with MASH and moderate or advanced liver fibrosis, once-weekly semaglutide at a dose of 2.4 mg improved liver histologic results. (Funded by Novo Nordisk; ClinicalTrials.gov number, NCT04822181.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A recent study reported significant effects on the resolution of MASLD without worsening of fibrosis, but also significant improvements in fibrosis without worsening of MASLD after 72 weeks of treatment with semaglutide.84”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [84]
In the citing paper
“Part 1 of a phase III trial investigating semaglutide for the treatment of MASH demonstrated resolution of steatohepatitis with no worsening of fibrosis in 63% of the semaglutide group, compared with 34% in the placebo group (68).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [68]
In the citing paper
“In addition, 37% of the semaglutide group showed improvement in fibrosis without worsening of steatohepatitis, compared with 23% in the placebo group.”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [68]
In the citing paper
“As for resmitirom, semaglutide is indicated for MASH patients with moderate to advanced liver fibrosis, but not liver cirrhosis (53).”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [53]
In the citing paper
“In the ESSENCE phase 3 trial, semaglutide showed a significant antifibrotic effect in patients with MASH and stage F2–F3 fibrosis (225).”
From Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages (2026) · cites this paper as [225]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Self-citationSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.06.003 · Cited by 3,100
Self-citationNon-alcoholic fatty liver disease
Powell, E. E., Wong, V. W.-S., & Rinella, M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32511-3 · Cited by 2,789
Self-citationRinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Self-citationA phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis
Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309000 · Cited by 2,084
Self-citationA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Self-citation
Cited by
Items 701–800 of 1,000
Bergheim, I., Cadranel, J. F. D., Chen, J., Ding, W., Eferl, R., García‐Ruiz, C., Jaeschke, H., Kazerouni, F., Lonardo, A., Mann, D. A., et al. (2026) · Exploration of Digestive Diseases · doi:10.37349/edd.2026.1005110
Impact of Obesity Medications on Gastric Function
Torres, J. A., & Sullivan, S. A. (2026) · Foregut The Journal of the American Foregut Society · doi:10.1177/26345161261417564
“27 These trials led to the approval of semaglutide for the treatment of patients with obesity and cardiovascular disease and patients with obesity and MASH with stage 2 or 3 fibrosis.”
Shaping the MASLD Evidence Base? Rethinking Geographic and Gender Representation in the Literature
Cheah, M. C. C., & Goh, G. (2026) · Digestive Diseases and Sciences · doi:10.1007/s10620-026-09719-7
Obesity in Living Kidney Donors from Risk to Ethics: Bridging Gaps in Evaluation and Management
Budhiraja, P., Bzoma, B., Đenić, A., Issa, N. S., McKee, K., Schinstock, C., Taler, S. J., Chakkera, H. A., Heimbach, J. K., Jadlowiec, C. C., et al. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000001030 · Cited by 2
Vafeidou, K., Koufakis, T., Stavropoulos, K., Zarfeiadou, M., Doumas, M. N., & Patoulias, D. (2026) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2026.2634086
Feng, Z., Chen, F., Xiao, J., Du, A., Deng, J., Wu, S., Zhang, Y., Li, X., Zheng, A., & Li, H. (2026) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.64898/2026.02.19.706502
Towards a better detection of people with metabolic dysfunction-associated steatotic liver disease
Heyens, L. J. M. (2026) · Research Publications (Maastricht University) · doi:10.26481/dis.20260224lh
Bariatric surgery in the era of modern obesity pharmacotherapy
Zhao, A. Y., & Dash, S. (2026) · Obesity and Endocrinology · doi:10.1093/obendo/wjag004
Supervía, M., de Murieta, E. S., Figueroa, J., Arroyo-Riaño, M. O., de Munain, M. L. L., de Miguel, C., Laxe, S., Marco, E., & Morata, A. B. (2026) · Rehabilitación · doi:10.1016/j.rh.2026.100968
Dominguez, C. L., & Rowell, J. V. (2026) · Medical Clinics of North America · doi:10.1016/j.mcna.2026.01.004
Sanyal, A. J., Parmar, K., de Oliveira, A. B. S., Jahagirdar, V., & Smirnova, E. (2026) · Research Square · doi:10.21203/rs.3.rs-8342646/v1
Self-citationvan Kleef, L. A., Michel, M., Savas, M., Pustjens, J., Theel, W. B., van Rossum, E. F. C., Paik, J. M., Younossi, Z. M., Janssen, H. L. A., Labenz, C., et al. (2026) · Gastro Hep Advances · doi:10.1016/j.gastha.2026.100912
“3,30 Another factor to take into account is whether it is primarily steatohepatitis with only limited fibrosis that requires treatment or more advanced fibrosis with limited steatohepatitis, since semaglutide seems more effective for MASH resolution and a THR-ß agonist for fibrosis regression.”
Implementing the 2025 AACE Obesity Algorithm: Bridging Guidelines With Real-World Clinical Practice
Sloan, L. A., Blanchette, J., & Patham, B. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.02.017
Real world tirzepatide treatment for fatty liver disease
Maung, S. T., & Wong, V. W. (2026) · Hepatology International · doi:10.1007/s12072-026-11065-9
Update in Outpatient General Internal Medicine: Practice-Changing Evidence Published in 2025
Andersen, C. A., Wieland, M. L., Bornstein, S. L., Huber, J. M., Sytsma, T. T., Bhuiyan, M. N., & Wingo, M. T. (2026) · The American Journal of Medicine · doi:10.1016/j.amjmed.2026.02.048
Association of Metabolic Dysfunction-Associated Steatohepatitis with Metabolic-Related Diseases
Diamantopoulos, L. N., Kalligeros, M., Isaacs, S. D., & Mauricio, D. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.12.001
SOUZA, M. M. X. D., Amaral, M. J. M., & Lima, L. C. V. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70642
Seko, Y., Arai, T., Takahashi, H., Toyoda, H., Hayashi, H., Yamaguchi, K., Iwaki, M., Yoneda, M., Shima, T., Fujii, H., et al. (2026) · Hepatology Research · doi:10.1111/hepr.70155 · Cited by 1
Zapletalová, A. T., Focko, B., Péč, M. J., Havaj, D. J., Skladaný, Ľ., Martinka, E., & Galajda, P. (2025) · Vnitřní lékařství · doi:10.36290/vnl.2025.098
MASLD: the missing link in the cardio-renal-metabolic syndrome
NELAJ, E., Xhixhabesi, K., Kecaj, I., & Gjata, M. (2026) · Archives of the Balkan Medical Union · doi:10.31688/abmu.2026.61.1.11
Fibrose hépatique : physiopathologie, diagnostic, pronostic
Gilgenkrantz, H., Bédossa, P., & Pol, S. (2026) · EMC - Hépatologie · doi:10.1016/s1155-1976(25)43565-7
Hwang, I., Kim, Y., & Lee, S. W. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70668
Blathra, E., & Liberopoulos, E. N. (2025) · Journal of Atherosclerosis Prevention and Treatment · doi:10.4103/aptj.aptj_16_25
Ong, J. P., Ghazinyan, H., Wong, V. W., & Eguchi, Y. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.01.006
Treatment of Modifiable Risks in Metabolic Dysfunction-Associated Steatotic Liver Disease
Kumar, S., Macedo, M. P., Roden, M., & Kashyap, S. R. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.01.003
Self-citationDiabetes und Metabolische Dysfunktion-assoziierte Steatotische Lebererkrankung
Stefan, N., & Roden, M. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01453-y
Self-citationMetabolische Lebererkrankungen bei Adipositas
Horn, P., & Tacke, F. (2026) · Aktuelle Ernährungsmedizin · doi:10.1055/a-2807-4330
“…72 Wochen bei 62,9 % der Teilnehmenden zu einer Resolution der Steatohepatitis ohne Verschlechterung der Fibrose (vs. 34,3 % in der Placebo-Gruppe) und in bis zu 36,8 % zu einer Verbesserung der Fibrose ohne Verschlechterung der Stea - tohepatitis (vs. 22,4 % in der Placebo-Gruppe) geführt [21].”
Semaglutide as a potential tool in pre–lung transplant weight loss optimization
Ali, R., Keyt, H., Solis‐Herrera, C., & Escobar-Vasco, M. (2026) · JCEM Case Reports · doi:10.1210/jcemcr/luag040
Bong, S. H. S., Teh, K. K., & Wong, V. W. (2026) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2026.0125 · Cited by 3
Papadia, F. S., Miggino, M., Gambella, A., Grillo, F., & Andorno, E. (2026) · Surgery Case Reports · doi:10.1016/j.sycrs.2026.100201
Silva, D. P., Carvalho, M. V. F., Llama, I., & Coelho, L. R. P. (2026) · International Journal of Health Management Review · doi:10.47172/ijhmreview.v12i1.481
Tesoro, N. A., Rivera, F. B., Bantayan, N. R. B., Magalong, J. V., Tomada, R., Wong, M. A., Tangco, G. A., Pine, P. L. S., Manha, J. K., Tanni, E. S., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101623
“The most clinically meaningful finding was the significantly increased likelihood of steatohepatitis resolution by about 25 % versus placebo, consistent with histology-based trials such as LEAN and sem-aglutide phase studies [17,22,46].”
Huang, Z., Ye, C.-H., Wu, C., Li, W., Deng, M., Lian, L., Huang, C., Wei, Y., Cao, Y., Shen, X., et al. (2026) · Liver International · doi:10.1111/liv.70634 · Cited by 2
Faheem, M. S. B., Cheema, S., Anwar, A., Rafay-ur-Rehman, M., Farhan, K., Mazhar, I., Shahid, H., Khan, F. U., Faheem, M. S. B., Usman, M., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9176897/v1
Götzinger, F., Stolte, T., Nestelberger, T., & Mahfoud, F. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag116
Passos, P. R. C., Motta, R. V., Filho, V. O. C., Noronha, M. M., Venâncio, R. C., Cançado, G. G. L., Adler, A., Cobbold, J., & Tomlinson, J. (2026) · Diabetes Care · doi:10.2337/dc26-0336 · Cited by 1
Kristensen, J. B., Nøhr-Meldgaard, J., Pors, S. E., Norlin, J., Veidal, S. S., Bendtsen, K. M., Niss, K., Andersen, M. W., Harder, L. M., Dalhoff, M. T., et al. (2026) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00011.2026 · Cited by 1
iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · International Journal of Cardiovascular Sciences · doi:10.36660/ijcs.20260056
Halley, R., Riley, C. J., Johnson, J., Round, M., Yeh, J., Khan, S., Boyd, A., Haydon, G. H., Mostafa, S. A., Newsome, P. N., et al. (2026) · Frontline Gastroenterology · doi:10.1136/flgastro-2026-103661
Self-citationAlawadi, F., Abdelgadir, E., Hassoun, A. A. K., Abusnana, S., Afandi, B. O., Aldahmani, K. M., Alkaabi, J., Bashier, A. M., Bayado, F., Belaila, B. A. B., et al. (2026) · Dubai Diabetes and Endocrinology Journal · doi:10.18502/ddej.v32i1.21067
Cho, D. (2026) · International Journal of Heart Failure · doi:10.36628/ijhf.2026.0002
“33) Finally, recent evidence suggests that NuSH therapies also address physical limitations caused by peripheral and musculo-skeletal comorbidities, which are crucial barriers to exercise in HF.”
Oh, J. H., Lee, J., Ahn, S. B., Kwon, E., Yoon, E. L., Lee, H. Y., Cho, S., & Jun, D. W. (2026) · Liver International · doi:10.1111/liv.70658
Zhang, Z.-R., She, L., Cao, Y., & Chen, Y.-W. (2026) · World Journal of Hepatology · doi:10.4254/wjh.v18.i4.116074
The Role of MicroRNAs in the Progression of Metabolic Dysfunction-associated Steatotic Liver Disease
Choi, J. H. (2026) · Journal of Digestive Cancer Research · doi:10.52927/jdcr.2026.14.1.82
Lin, C., Chen, W., Liu, S. X., Cao, B., Ge, Y., Li, Y., Liu, Y., Guo, T., Xu, J., & Wang, C. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-115236
“33 34 Previous studies have indicated that GLP-1 RAs alleviate NAFLD primarily through mechanisms involving insulin resistance, lipid metabolism, oxidative stress and gut-liver axis homeostasis.”
Ageing liver in the era of MASLD: risks, mechanisms and treatment opportunities
Alqahtani, S. A., Schneider, C. V., & Schattenberg, J. M. (2026) · Frontline Gastroenterology · doi:10.1136/flgastro-2026-103677
Semaglutide and Its Potential Hepatoprotective Effects Against Acute Drug-Induced Liver Injury
Charatsi, E., Liberopoulos, E. N., Pergialiotis, V., Kontzoglou, K., Kykalos, S., & Iliopoulos, D. (2026) · Cureus · doi:10.7759/cureus.107715
“Improvement of fibrosis with no progression of MASH occurred in 36.8% of patients in the semaglutide group versus 22.4% in the placebo group (p 0.001) [18,19].”
InfluentialNuevos horizontes en la comprensión de la disfunción metabólica asociada al hígado graso
Rubiano, J. F. M., Cardona, S. L., Betancur, S. S., & Rincón, A. R. (2026) · Revista Colombiana de Endocrinología Diabetes & Metabolismo · doi:10.53853/encr.13.1.911
“El perfil de seguridad fue consistente con lo conocido de los agonistas GLP-1, predominando efectos gastrointestinales leves a moderados y bajas tasas de discontinuación (41).”
Modulating hepatic stellate cell senescence: A promising therapeutic strategy for liver fibrosis
Sharmila, M., Harini, K. S., & Ezhilarasan, D. (2026) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2026.04.006
Liu, J., Liu, R., Shi, Y., Sun, Y., Zhang, Z., Mao, M., Chang, L., Zhang, T., Han, C., Wu, J., et al. (2026) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5c01019
Torre, E., Matteo, S. D., Martinotti, C., Bruno, G. M., Cabrino, A., Fogliati, E., Giusti, A., Barbieri, M., Bottaro, L. C., & Colombo, G. L. (2026) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s585328
“10 In this study, reduction in liver fibrosis without worsening of steatohepatitis was observed in 36.8% of patients treated with semaglutide and in 22.4% of those receiving placebo, corresponding to an estimated absolute difference of 14.4% (95% CI, 7.5–21.3; P<0.001).”
InfluentialFeng, G., He, N., Yang, B. B., & Liu, Y. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70830
Ampadu, F. A., Patil, N. Y., Eeda, V., Rus, I., Jung, W., Abushukair, H. M., Ali, A., Aguilar-Sánchez, Y., Oh, T. G., Awasthi, V., et al. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101886
“4 7 Therefore, identification of novel targets and development of small-molecule drugs that can treat the entire morphologic and metabolic manifestations associated with MASH are warranted.”
GCSH promotes MASH progression by regulating cuproptosis through the glycine–GSH metabolic pathway
Fu, X., Li, Y., Chen, J., 殷宝龙, Nasrin, M., Huo, R., & Tian, S. (2026) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2026.04.161
Njeim, R., Abureesh, O., Sohail, A., Tam, R., & Deeb, L. S. (2026) · Livers · doi:10.3390/livers6030035
“%) compared to those on a placebo [45,50].”
9.4-T MRI monitoring of early MASH progression and therapeutic response in a prefibrotic mouse model
Li, Y., Wu, Y. N., Wang, G., Zheng, Y., Tong, H., Yang, H., Yu, J., Shi, P., Zheng, Y., Zhou, L., et al. (2026) · European Radiology Experimental · doi:10.1186/s41747-026-00719-w
Embedding MASLD Risk Stratification in Primary Care: Results from a Community Health Center PilotPreprint
Wexler, R. P., Vuddanda, P., Trilianos, P., & Mohanty, A. (2026) · Research Square · doi:10.21203/rs.3.rs-9408563/v1
Steatotic liver disease: a dynamic spectrum, not a static state
Spearman, C. W. (2026) · South African journal of gastroenterology and hepatology. · doi:10.36303/sajgh.4337
Yurukova, N., & Sultani, B. (2026) · Cureus · doi:10.7759/cureus.108793
“Several studies in patients with diabetes or obesity have reported improvements in liver enzymes and hepatic steatosis with GLP1RAs, supporting interest in their potential role in metabolic dysfunction-associated steatohepatitis (MASH) [1,11,12].”
Adipose tissue inflammation: a main driver of metabolic dysfunction-associated steatohepatitis
Vachliotis, I. D., & Pοlyzos, S. A. (2026) · Immunometabolism · doi:10.1097/in9.0000000000000082
Wu, J., Lin, Y.-M., Hsu, W., Liu, T.-H., Tsai, Y., Huang, P., Chuang, M., & Lai, C. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1769425
“Semaglutide has been shown to significantly reduce liver steatosis and improve histological activity in patients with MASH in a randomized trial (Sanyal et al., 2025), while liraglutide improved histological features of NASH and was associated with higher rates of resolution compared with placebo…”
Alam, A. (2026) · Bangladesh Journal of Endocrinology and Metabolism · doi:10.4103/bjem.bjem_17_26
РОЛЬ СЕЛЕКТИВНИХ АГОНІСТІВ THR-β У МЕТАБОЛІЧНОМУ РЕМОДЕЛЮВАННІ ТА РЕВЕРСІЇ ФІБРОЗУ ПЕЧІНКИ ПРИ MASLD
Шумко, Г., Bolboka, I., Варваринець, Р., & Тарасюк, Д. (2026) · Перспективи та інновації науки · doi:10.52058/2786-4952-2026-4(62)-3102-3111
Wei, W., Graf, R., Wang, Y., Oalmann, C. J., Lau, J. T., Wang, X., Chien, M., Conrad, M. C., Simon, J., Ganguly, S., et al. (2026) · Molecular Metabolism · doi:10.1016/j.molmet.2026.102430
Kaneko, Y., Hori, T., Miyataka, K., Asai, T., Hara, T., Yamagami, H., Otoda, T., Yuasa, T., Kuroda, A., Nakamura, S., et al. (2026) · Biomedicines · doi:10.3390/biomedicines14051150
“Contrastingly, GLP-1RAs have recently been reported to improve liver fibrosis [50]; however, our study showed a positive correlation between GLP-1RA use and HbA1c fluctuations.”
Novel Pharmacological and Nanotechnology-Based Therapeutic Strategies for MASLD
Villaseñor-Tapia, E. C., Franco-Acevedo, A., Rosas-Campos, R., & Armendáriz‐Borunda, J. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18050584
Li, M., Zhang, J., Yang, Y., Tian, S., Cheng, X., Li, Q., Li, P., Zhou, S., Shen, H., Liu, Z., et al. (2026) · Gut · doi:10.1136/gutjnl-2025-337802
“34 35 38 Therefore, there is an urgent need to identify new molecular regulators and therapeutic targets for this disease.”
Lee, J. W., Oh, E.-J., Cho, S., Kang, J.-H., Gwak, S.-H., Shin, W., Yoon, S., Han, Y., Kim, J., & Kim, K. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179008
Screening for Advanced Liver Disease in Type 2 Diabetes: Time for Systematic Implementation
Solís‐Muñoz, P. (2026) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2026.12025/2026
Valinotti, E., Vera, L. D. V., Ovelar, H. L., Gómez, F. R., Benítez, A. G., Mendieta, F. F., & Fernández, N. L. G. (2026) · Scripta Scientia · doi:10.66201/ss.v1.26
A global commitment to addressing chronic liver disease
García-Larsen, V., Wickramasinghe, K., & Hennis, A. J. (2026) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2026.101723
“…for obesity reduction, glucagon-like-peptide-1 (GLP-1) receptor agonist medications are also proving effective in attenuating or reversing MASH, 10 and their combination with lifestyle interventions that include Mediterranean diet and exercise can accelerate weight loss and improve markers of…”
Application and interpretation of non-invasive testing in MetALD
Chan, W., Liu, K., Goh, G. B., & Wong, V. W. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2026.30 · Cited by 1
If GLP-1s are “longevity drugs,” the evidence bar must change—carefully
Jones, C. H., & Dolsten, M. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104707
The Evolution of MASLD Management: From Revised Nomenclature to Disease-Modifying Therapies
Kornatowska, K., Kopciał, S., Wiekiera, M., Jasiuk, A., Budzik, P., Tyniec, M., & Morshed, K. (2026) · Gastroenterology Insights · doi:10.3390/gastroent17020033
Sozaeva, Z. Y., Атаева, М. В., Salatova, E. O., Alikova, I. K., Dolgaya, A. E., Magomedov, A. G., Hafsi, K. R., Shomakhov, N.-M. A., Pshukova, E. M., & Sharaf, Y. N. (2026) · Journal Of Biochemical Technology · doi:10.51847/ybhmiqqb3d
Chen, Z., Yang, Q., Liu, J. S., Zhao, H., Ying, H., Liu, H., Huang, L., Lin, H. Y., Wang, S., Li, M., et al. (2026) · BMC Medicine · doi:10.1186/s12916-026-04888-8
McGilvrey, M. I., Chew, S., Siddiqui, M. F., Bronson, R., Uslu, M., Ye, S., Ospina, O., Mcpherson, A., Diel, K., Dogsa, M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.22.726943
Laique, S. N., Bansal, P., Nadeem, M. A., Wehrle, C. J., Verma, S., Giuseppucci, A., Berber, B., Sanha, V., Hellickson, K., Maura, G., et al. (2026) · Liver Transplantation · doi:10.1097/lvt.0000000000000911 · Cited by 1
Glucagon-Like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease: A Narrative Review
Desai, A., Habib, H., Wahbeh, L., & Farraye, F. A. (2026) · Gastro Hep Advances · doi:10.1016/j.gastha.2026.101023
Le, D., Kilpatrick, M., Kraft, W. K., Grams, M. E., Jaar, B. G., & Shin, J.-I. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.106618
GLP-1 and Nutrient Stimulated Hormone Targets: Beyond Weight Loss
Ryan, D. H. (2026) · Dermatologic Surgery · doi:10.1097/dss.0000000000005113
Nery, F. (2026) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000003185
Hussain, N., & Haddad, A. H. I. A. (2026) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2026.100338
Palmer, M., Hashiguchi, T., Arman, A. C., Shirakata, Y., E.Buss, N., & Lalezari, J. P. (2026) · ASEAN Journal of Psychiatry · doi:10.54615/2231-7805.26.15.281
Hepatic steatosis: A pandemic disease causing serious secondary diseases
Canbay, A., Figge, A., Patsalis, P., Baars, T., Özcürümez, M. K., & Götze, O. (2026) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2026.0074
Zhao, H. (2026) · Cureus · doi:10.7759/cureus.110011
“Semaglutide has also shown efficacy for MASH resolution in a large phase 3 trial, supporting the clinical relevance of metabolic therapies in this field [9].”
TGFβ activity stabilizes ACC1 to increase de novo lipogenesis in metabolic liver disease
Mayfield, B., Yagashita, Y., Kang, J., Zhu, C., Mira, S., Kendall, T. J., Sun, Q., Meincke, M. E., Raphael, D., Li, M., et al. (2026) · Molecular Metabolism · doi:10.1016/j.molmet.2026.102389
Yu, L.-Y., & Zhang, X. (2026) · World Journal of Hepatology · doi:10.4254/wjh.117543
A therapeutic turning point in metabolic liver disease
Gautheron, J., & Duarte‐Rojo, A. (2026) · npj gut and liver. · doi:10.1038/s44355-026-00065-z
Hu, J.-H., Chang, M., Huang, T., Liu, N., & Hsieh, Y.-Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1874720
Santiago, I. D. C., Lemos, J. D. A., Silva, I. M., Oliveira, A. E. M. D. F. M., & Ferreira, D. S. (2026) · Livers · doi:10.3390/livers6030048
“…hormone receptor-β agonist resmetirom [7], as well as the clinical investigation of farnesoid X receptor (FXR) agonists, glucagon-like peptide-1 (GLP-1) receptor agonists, especially semaglutide, and other metabolic modulators that aim to improve hepatic steatosis, inflammation, and fibrosis [1,8].”
GLP-1 drugs like Ozempic show promise for more than weight loss. But what’s science vs hype?
Joyce, P. (2026) · The Conversation · doi:10.64628/aa.y3rgpa3qr
Zhao, P., Zou, J., Li, Y., Liu, S., Zhao, Z. H., & Huang, X. (2026) · Hepatology International · doi:10.1007/s12072-026-11101-8
“Patients with a NAS of 5 or more were diagnosed with definite MASH, and MASH patients with a fibrosis stage ≥ 2 were considered as fibrotic MASH [19, 20].”
La endocrinología en el epicentro de la esteatosis hepática metabólica
Rubio, M. Á., & Martín, J. E. S. (2026) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2026.501847
Slover, W. K., Huang, A. V., D’Souza, S. M., Oldfield, E. C., & Johnson, D. A. (2026) · Journal of Translational Gastroenterology · doi:10.14218/jtg.2026.00003 · Cited by 1
Zheng, C., Muir, K. C., Reddy, R., Stone, C. R., Harris, D. D., & Sellke, F. W. (2026) · Surgery · doi:10.1016/j.surg.2026.110369
Obesity, Liver Disease, and the Patient Voice: A Clinical Dialogue Podcast
Poddar, M., & Nadglowski, J. F. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03648-7
“Obesity treatments, especially pharmaco-therapy and bariatric surgery, fortunately have actually been shown to improve MASH and inflammation in the liver [12–14] because we’re treating that obesity, and because obesity and excess fat are the underlying causes of so many of these issues.”
Altés, A., Moreno, Ó., Sastre-Belío, M., Rodríguez-Urgellés, E., Pérez-Alcántara, F., Larsen, S., Martín‐Lorenzo, A., Sandín, M., & Vidal, J. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03644-x
Unleashing innovative cross-organ fibrosis therapies by harnessing the omics revolution
Lebeaupin, C., Donahue, K. L., Dower, K., Wynn, T. A., Hart, K. M., & Fabre, T. (2026) · JCI Insight · doi:10.1172/jci.insight.200155
“…have shown improved fibrosis in only a small percentage of patients — resmetirom: ~12% placebo adjusted (14), semaglutide: 14.4% placebo adjusted (15), obeticholic acid: 11% placebo adjusted at high dose (16), pegozafermin (modified FGF21): 20% at high dose (17), efruxifermin: 10% and 16%…”
Influential
Metadata
- Authors
- Sanyal, A. J., Newsome, P. N., Kliers, I., Østergaard, L. H., Long, M. T., Kjær, M. S., Cali, A. M. G., Bugianesi, E., Rinella, M. E., Roden, M., & Ratziu, V.
- Affiliations
- Virginia Commonwealth University (US)
- King's College London (GB)
- Novo Nordisk (Denmark) (DK)
- University of Turin (IT)
- University of Chicago (US)
- Düsseldorf University Hospital (DE)
- Inserm (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-06-05
- Volume
- 392
- Issue
- 21
- Pages
- 2089-2099
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4409963211
- Cited by
- 1,115
- References
- 39
- Citations by year
- 2026: 813 · 2025: 302
- FWCI
- 767.51
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Scopus (Elsevier) (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, nonalcoholic steatohepatitis, GLP-1 receptor agonists, liver fibrosis, weight loss, body mass index, non-alcoholic fatty liver disease, fibrosis regression, interim analysis, multiple testing correction, non-invasive fibrosis markers
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Adult, Aged, Biopsy, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Injections, Subcutaneous, Liver, Liver Cirrhosis, Male, Middle Aged, Severity of Illness Index, Treatment Outcome, Glucagon-Like Peptide 1, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.